Horton, H. R. et al. (eds) Principles of Biochemistry (Pearson Press, 2006).
Latham, M. C. (ed) Human Nutrition in the Developing World (Food & Agriculture Org. Press, 1997).
Vettore, L., Westbrook, R. L. & Tennant, D. A. New aspects of amino acid metabolism in cancer. Br. J. Cancer 122, 150–156 (2020).
Lieu, E. L., Nguyen, T., Rhyne, S. & Kim, J. Amino acids in cancer. Exp. Mol. Med. 52, 15–30 (2020).
Sun, L., Sadighi Akha, A. A., Miller, R. A. & Harper, J. M. Life-span extension in mice by preweaning food restriction and by methionine restriction in middle age. J. Gerontol. A Biol. Sci. Med. Sci. 64, 711–722 (2009).
Miller, R. A. et al. Methionine-deficient diet extends mouse lifespan, slows immune and lens aging, alters glucose, T4, IGF-I and insulin levels, and increases hepatocyte MIF levels and stress resistance. Aging Cell 4, 119–125 (2005).
Orentreich, N., Matias, J. R., DeFelice, A. & Zimmerman, J. A. Low methionine ingestion by rats extends life span. J. Nutr. 123, 269–274 (1993).
Zimmerman, J. A., Malloy, V., Krajcik, R. & Orentreich, N. Nutritional control of aging. Exp. Gerontol. 38, 47–52 (2003).
Choi, B. H. & Coloff, J. L. The diverse functions of non-essential amino acids in cancer. Cancers 11, 675 (2019).
Newgard, C. B. Metabolomics and metabolic diseases: where do we stand? Cell Metab. 25, 43–56 (2017).
White, P. J. et al. Insulin action, type 2 diabetes, and branched-chain amino acids: a two-way street. Mol. Metab. 52, 101261 (2021).
Wu, B. et al. Mitochondrial aspartate regulates TNF biogenesis and autoimmune tissue inflammation. Nat. Immunol. 22, 1551–1562 (2021).
Ruzzo, E. K. et al. Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy. Neuron. 80, 429–441 (2013).
Alfadhel, M. et al. Asparagine synthetase deficiency: new inborn errors of metabolism. JIMD Rep. 22, 11–16 (2015).
Ben-Salem, S. et al. Asparagine synthetase deficiency detected by whole exome sequencing causes congenital microcephaly, epileptic encephalopathy and psychomotor delay. Metab. Brain Dis. 30, 687–694 (2015).
Palmer, E. E. et al. Asparagine Synthetase Deficiency causes reduced proliferation of cells under conditions of limited asparagine. Mol. Genet. Metab. 116, 178–186 (2015).
Seidahmed, M. Z. et al. Hyperekplexia, microcephaly and simplified gyral pattern caused by novel ASNS mutations, case report. BMC Neurol. 16, 105 (2016).
Gataullina, S. et al. Epileptic phenotype of two siblings with asparagine synthesis deficiency mimics neonatal pyridoxine-dependent epilepsy. Neuropediatrics 47, 399–403 (2016).
Piao, L. et al. Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension. J. Mol. Med. 91, 1185–1197 (2013).
Böger, R. H. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc. Res. 59, 824–833 (2003).
Young, V. R. Adult amino acid requirements: the case for a major revision in current recommendations. J. Nutr. 124, 1517S–1523S (1994).
Furst, P. & Stehle, P. What are the essential elements needed for the determination of amino acid requirements in humans? J. Nutr. 134, 1558S–1565S (2004).
Sakami, W. & Harrington, H. Amino acid metabolism. Annu. Rev. Biochem. 32, 355–398 (1963).
Brosnan, J. T. Glutamate, at the interface between amino acid and carbohydrate metabolism. J. Nutr. 130, 988S–990S (2000).
Forsberg, H. & Ljungdahl, P. O. Sensors of extracellular nutrients in Saccharomyces cerevisiae. Curr. Genet. 40, 91–109 (2001).
Christie, G. R., Hyde, R. & Hundal, H. S. Regulation of amino acid transporters by amino acid availability. Curr. Opin. Clin. Nutr. Metab. Care 4, 425–431 (2001).
Hediger, M. A., Clémençon, B., Burrier, R. E. & Bruford, E. A. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol. Asp. Med. 34, 95–107 (2013).
Bröer, S. Adaptation of plasma membrane amino acid transport mechanisms to physiological demands. Pflügers Arch. 444, 457–466 (2002).
Hyde, R., Taylor, P. M. & Hundal, H. S. Amino acid transporters: roles in amino acid sensing and signalling in animal cells. Biochem. J. 373, 1–18 (2003).
Kandasamy, P., Gyimesi, G., Kanai, Y. & Hediger, M. A. Amino acid transporters revisited: New views in health and disease. Trends Biochem. Sci. 43, 752–789 (2018).
Ou, D. et al. Dietary supplementation with zinc oxide decreases expression of the stem cell factor in the small intestine of weanling pigs. J. Nutr. Biochem. 18, 820–826 (2007).
Marc Rhoads, J. & Wu, G. Glutamine, arginine, and leucine signaling in the intestine. Amino Acids 37, 111–122 (2009).
Jobgen, W. S., Fried, S. K., Fu, W. J., Meininger, C. J. & Wu, G. Regulatory role for the arginine-nitric oxide pathway in metabolism of energy substrates. J. Nutr. Biochem. 17, 571–588 (2006).
Galli, F. Amino acid and protein modification by oxygen and nitrogen species. Amino Acids 42, 1–4 (2012).
Mannick, J. Regulation of apoptosis by protein S-nitrosylation. Amino Acids 32, 523 (2007).
Liao, X. H., Majithia, A., Huang, X. & Kimmel, A. R. Growth control via TOR kinase signaling, an intracellular sensor of amino acid and energy availability, with crosstalk potential to proline metabolism. Amino Acids 35, 761–770 (2008).
Escobar, J. et al. Regulation of cardiac and skeletal muscle protein synthesis by individual branched-chain amino acids in neonatal pigs. Am. J. Physiol. – Endocrinol. Metab. 290, E612–E621 (2006).
Meijer, A. J. & Dubbelhuis, P. F. Amino acid signalling and the integration of metabolism. Biochem. Biophys. Res. Commun. 313, 397–403 (2004).
Yao, K. et al. Dietary arginine supplementation increases mTOR signaling activity in skeletal muscle of neonatal pigs. J. Nutr. 138, 867–872 (2008).
Wu, G. & Morris, S. M. Jr. Arginine metabolism: nitric oxide and beyond. Biochem. J. 336, 1–17 (1998).
Sinclair, L. V. et al. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat. Immunol. 14, 500–508 (2013).
Lee, G. K. et al. Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology. 107, 452–460 (2002).
Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633–642 (2005).
Rodriguez, P. C., Quiceno, D. G. & Ochoa, A. C. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109, 1568–1573 (2007).
Ichihara, A. & Koyama, E. Transaminase of branched chain amino acids. I. Branched chain amino acids-alpha-ketoglutarate transaminase. J. Biochem. 59, 160–169 (1966).
Wolfson, R. L. et al. Sestrin2 is a leucine sensor for the mTORC1 pathway. Science 351, 43–48 (2016).
Buse, M. G., Atwell, R. & Mancusi, V. In vitro effect of branched chain amino acids on the ribosomal cycle in muscles of fasted rats. Horm. Metab. Res. 11, 289–292 (1979).
Skaper, S. D., Molden, D. P. & Seegmiller, J. E. Maple syrup urine disease: branched-chain amino acid concentrations and metabolism in cultured human lymphoblasts. Biochem. Genet. 14, 527–539 (1976).
Calder, P. C. Branched-chain amino acids and immunity. J. Nutr. 136, 288S–293S (2006).
Budhathoki, S. et al. Association of plasma concentrations of branched-chain amino acids with risk of colorectal adenoma in a large Japanese population. Ann. Oncol. 28, 818–823 (2017).
Mayers, J. R. et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat. Med. 20, 1193–1198 (2014).
Mayers, J. R. et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science 353, 1161–1165 (2016).
Lei, M. Z. et al. Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth. Signal Transduct. Target Ther. 5, 70 (2020).
Li, J.-T. et al. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma. Nat. Cell Biol. 22, 167–174 (2020).
Shafei, M. A. et al. BCATc modulates crosstalk between the PI3K/Akt and the Ras/ERK pathway regulating proliferation in triple negative breast cancer. Oncotarget 11, 1971 (2020).
Holmstrom, S. R. & Olive, K. P. Protein breakdown precedes pancreatic tumor development. Nat. Med. 20, 1097–1099 (2014).
Zhu, Z. et al. Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. Nat. Metab. 2, 775–792 (2020).
Wang, Y. et al. BCKDK alters the metabolism of non-small cell lung cancer. Transl. Lung Cancer Res. 10, 4459–4476 (2021).
Chi, R. et al. Elevated BCAA suppresses the development and metastasis of breast cancer. Front. Oncol. 12, 887257 (2022).
Shafei, M. A. et al. Differential expression of the BCAT isoforms between breast cancer subtypes. Breast Cancer 28, 592–607 (2021).
Zhang, L. & Han, J. Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function. Biochem. Biophys. Res. Commun. 486, 224–231 (2017).
Silva, L. S. et al. Branched‐chain ketoacids secreted by glioblastoma cells via MCT 1 modulate macrophage phenotype. EMBO Rep. 18, 2172–2185 (2017).
Zhang, B. et al. Regulation of branched-chain amino acid metabolism by hypoxia-inducible factor in glioblastoma. Cell Mol. Life Sci. 78, 195–206 (2021).
Zhang, B. et al. Targeting BCAT1 combined with alpha-ketoglutarate triggers metabolic synthetic lethality in glioblastoma. Cancer Res. 82, 2388–2402 (2022).
Goto, M. et al. Structural determinants for branched-chain aminotransferase isozyme-specific inhibition by the anticonvulsant drug gabapentin. J. Biol. Chem. 280, 37246–37256 (2005).
Conway, M. E., Coles, S. J., Islam, M. M. & Hutson, S. M. Regulatory control of human cytosolic branched-chain aminotransferase by oxidation and S-glutathionylation and its interactions with redox sensitive neuronal proteins. Biochemistry 47, 5465–5479 (2008).
Yu, D. et al. The adverse metabolic effects of branched-chain amino acids are mediated by isoleucine and valine. Cell Metab. 33, 905–922.e906 (2021).
White, P. J. et al. The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase. Cell Metab. 27, 1281–1293.e1287 (2018).
Ma, Q.-X. et al. BCAA–BCKA axis regulates WAT browning through acetylation of PRDM16. Nat. Metab. 4, 106–122 (2022).
Kitaura, Y. et al. Antihypertensive drug valsartan as a novel BDK inhibitor. Pharmacol. Res. 167, 105518 (2021).
Sun, H. et al. Catabolic defect of branched-chain amino acids promotes heart failure. Circulation. 133, 2038–2049 (2016).
Ogawa, T. et al. Downregulation of extramitochondrial BCKDH and its uncoupling from AMP deaminase in type 2 diabetic OLETF rat hearts. Physiol. Rep. 11, e15608 (2023).
Plauth, M. et al. Characteristic pattern of free amino acids in plasma and skeletal muscle in stable hepatic cirrhosis. Hepatogastroenterology 37, 135–139 (1990).
Holecek, M. Ammonia and amino acid profiles in liver cirrhosis: effects of variables leading to hepatic encephalopathy. Nutrition 31, 14–20 (2015).
van den Berg, E. H. et al. Non-alcoholic fatty liver disease and risk of incident type 2 diabetes: role of circulating branched-chain amino acids. Nutrients 11, 705 (2019).
Tajiri, K. & Shimizu, Y. Branched-chain amino acids in liver diseases. Transl. Gastroenterol. Hepatol. 3, 47 (2018).
Honda, M. et al. Malnutrition impairs interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C. Gastroenterology 141, 128–140.e122 (2011).
Singh Tejavath, A. et al. Impact of Branched Chain Amino Acid on Muscle Mass, Muscle Strength, Physical Performance, Combined Survival, and Maintenance of Liver Function Changes in Laboratory and Prognostic Markers on Sarcopenic Patients With Liver Cirrhosis (BCAAS Study): A Randomized Clinical Trial. Front. Nutr. 8, 715795 (2021).
Alvestrand, A., Furst, P. & Bergstrom, J. Plasma and muscle free amino acids in uremia: influence of nutrition with amino acids. Clin. Nephrol. 18, 297–305 (1982).
Schauder, P. et al. Blood levels of branched-chain amino acids and alpha-ketoacids in uremic patients given keto analogues of essential amino acids. Am. J. Clin. Nutr. 33, 1660–1666 (1980).
Kumar, M. A. et al. Branched chain amino acid profile in early chronic kidney disease. Saudi J. Kidney Dis. Transpl. 23, 1202–1207 (2012).
Suliman, M. E. et al. Inflammation contributes to low plasma amino acid concentrations in patients with chronic kidney disease. Am. J. Clin. Nutr. 82, 342–349 (2005).
Grimble, R. F. Nutritional modulation of immune function. Proc. Nutr. Soc. 60, 389–397 (2001).
Cano, N. J., Fouque, D. & Leverve, X. M. Application of branched-chain amino acids in human pathological states: renal failure. J. Nutr. 136, 299S–307S (2006).
GDR, H. B., Sharon, N. & Australia, E. W. Nomenclature and symbolism for amino acids and peptides. Pure Appl. Chem. 56, 595–624 (1984).
Berg, J. M., Tymoczko, J. L. & Stryer, L. (eds) Biochemistry (W. H. Freeman. Press, 2002).
Krall, A. S. et al. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nat. Commun. 7, 11457 (2016).
Matlashewski, G. et al. Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J. 3, 3257–3262 (1984).
Isobe, M. et al. Localization of gene for human p53 tumour antigen to band 17p13. Nature 320, 84–85 (1986).
Kern, S. E. et al. Identification of p53 as a sequence-specific DNA-binding protein. Science 252, 1708–1711 (1991).
Deng, L. et al. p53-mediated control of aspartate-asparagine homeostasis dictates LKB1 activity and modulates cell survival. Nat. Commun. 11, 1755 (2020).
Garcia-Bermudez, J. et al. Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours. Nat. Cell Biol. 20, 775–781 (2018).
Sullivan, L. B. et al. Aspartate is an endogenous metabolic limitation for tumour growth. Nat. Cell Biol. 20, 782–788 (2018).
Sun, J. et al. SLC1A3 contributes to L-asparaginase resistance in solid tumors. EMBO J. 38, e102147 (2019).
Xu, L. et al. SLC1A3 promotes gastric cancer progression via the PI3K/AKT signalling pathway. J. Cell. Mol. Med. 24, 14392–14404 (2020).
Wong, C. C. et al. SLC25A22 promotes proliferation and survival of colorectal cancer cells with KRAS mutations and xenograft tumor progression in mice via intracellular synthesis of aspartate. Gastroenterology 151, 945–960.e946 (2016).
Knott, S. R. et al. Asparagine bioavailability governs metastasis in a model of breast cancer. Nature 554, 378–381 (2018).
Gwinn, D. M. et al. Oncogenic KRAS regulates amino acid homeostasis and asparagine biosynthesis via ATF4 and alters sensitivity to L-asparaginase. Cancer Cell 33, 91–107.e106 (2018).
Hope, H. C. et al. Coordination of asparagine uptake and asparagine synthetase expression modulates CD8+ T cell activation. JCI Insight 6, e137761 (2021).
Wu, J. et al. Asparagine enhances LCK signalling to potentiate CD8+ T-cell activation and anti-tumour responses. Nat. Cell Biol. 23, 75–86 (2021).
Williams, R. T. et al. ZBTB1 regulates asparagine synthesis and leukemia cell response to L-asparaginase. Cell Metab. 31, 852–861.e856 (2020).
Cools, J. Improvements in the survival of children and adolescents with acute lymphoblastic leukemia. Haematologica 97, 635 (2012).
Haskell, C. M. et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N. Engl. J. Med. 281, 1028–1034 (1969).
Hays, J. L. et al. A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: early closure for safety. Mol. Clin. Oncol. 1, 565–569 (2013).
Tong, W. H. et al. Toxicity of very prolonged PEGasparaginase and Erwinia asparaginase courses in relation to asparaginase activity levels with a special focus on dyslipidemia. Blood 124, 2256 (2014).
Heitink-Polle, K. M. et al. High incidence of symptomatic hyperammonemia in children with acute lymphoblastic leukemia receiving pegylated asparaginase. JIMD Rep. 7, 103–108 (2013).
Grigoryan, R. S. et al. Changes of amino acid serum levels in pediatric patients with higher-risk acute lymphoblastic leukemia (CCG-1961). Vivo 18, 107–112 (2004).
Feldmann, M., Brennan, F. M. & Maini, R. N. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14, 397–440 (1996).
Maini, R. N. & Taylor, P. C. Anti-cytokine therapy for rheumatoid arthritis. Annu. Rev. Med. 51, 207–229 (2000).
FDA, U. & FDA. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. FDA, (2021).
Dhillon, S. Tofacitinib: a review in rheumatoid arthritis. Drugs 77, 1987–2001 (2017).
Rogler, G. Efficacy of JAK inhibitors in Crohn’s Disease. J. Crohns Colitis 14, S746–S754 (2020).
Alrifai, M. T. & Alfadhel, M. Worsening of seizures after asparagine supplementation in a child with asparagine synthetase deficiency. Pediatr. Neurol. 58, 98–100 (2016).
Hawkins, R. A., O’Kane, R. L., Simpson, I. A. & Vina, J. R. Structure of the blood-brain barrier and its role in the transport of amino acids. J. Nutr. 136, 218S–226S (2006).
Tang, W., Liu, D., Traynelis, S. F. & Yuan, H. Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders. Neuropharmacology 177, 108247 (2020).
XiangWei, W., Jiang, Y. & Yuan, H. De novo mutations and rare variants occurring in NMDA receptors. Curr. Opin. Physiol. 2, 27–35 (2018).
Liang, R., Robb, F. T. & Onstott, T. C. Aspartic acid racemization and repair in the survival and recovery of hyperthermophiles after prolonged starvation at high temperature. FEMS Microbiol. Ecol. 97, fiab112 (2021).
Errico, F. et al. D-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801. J. Neurosci. 28, 10404–10414 (2008).
Errico, F. et al. A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice. Transl. Psychiatry 5, e512–e512 (2015).
Sacchi, S. et al. Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity. Sci. Rep. 7, 46288 (2017).
Meyers, L. D., Hellwig, J. P. & Otten, J. J. Dietary Reference Intakes: the Essential Guide to Nutrient Requirements (National Academies Press, 2006).
Newsholme, P. et al. Glutamine and glutamate as vital metabolites. Braz. J. Med. Biol. 36, 153–163 (2003).
Corbet, C. & Feron, O. Metabolic and mind shifts: from glucose to glutamine and acetate addictions in cancer. Curr. Opin. Clin. Nutr. Metab. Care 18, 346–353 (2015).
Yuneva, M. et al. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J. Cell Biol. 178, 93–105 (2007).
Cruzat, V. et al. Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients 10, 1564 (2018).
Xiao, D. et al. The glutamine-alpha-ketoglutarate (AKG) metabolism and its nutritional implications. Amino Acids 48, 2067–2080 (2016).
Yoo, H. C., Yu, Y. C., Sung, Y. & Han, J. M. Glutamine reliance in cell metabolism. Exp. Mol. Med. 52, 1496–1516 (2020).
Yang, L., Venneti, S. & Nagrath, D. Glutaminolysis: a hallmark of cancer metabolism. Annu. Rev. Biomed. Eng. 19, 163–194 (2017).
Mukha, A. et al. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. Theranostics 11, 7844–7868 (2021).
Amaya, M. L. et al. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Blood 139, 584–596 (2022).
Tajan, M. et al. A role for p53 in the adaptation to glutamine starvation through the expression of SLC1A3. Cell Metab. 28, 721–736.e726 (2018).
Kilberg, M. S., Shan, J. & Su, N. ATF4-dependent transcription mediates signaling of amino acid limitation. Trends Endocrinol. Metab. 20, 436–443 (2009).
Zhang, W. et al. RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11. J. Clin. Investig. 131, e152067 (2021).
Timmerman, L. A. et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24, 450–465 (2013).
Koppula, P., Zhang, Y., Zhuang, L. & Gan, B. Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. 38, 1–13 (2018).
Zhang, L. et al. Overexpression of SLC7A11: a novel oncogene and an indicator of unfavorable prognosis for liver carcinoma. Future Oncol. 14, 927–936 (2018).
Badgley, M. A. et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science 368, 85–89 (2020).
Márquez, J., Matés, J. M. & Campos-Sandoval, J. A. Glutaminases. Adv. Neurobiol. 13, 133–171 (2016).
Li, Y. et al. GOT2 silencing promotes reprogramming of glutamine metabolism and sensitizes hepatocellular carcinoma to glutaminase inhibitors. Cancer Res. 82, 3223–3235 (2022).
Xu, L. et al. A glutaminase isoform switch drives therapeutic resistance and disease progression of prostate cancer. Proc. Natl Acad. Sci. USA 118, e2012748118 (2021).
Wu, S. et al. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nat. Cancer 2, 189–200 (2021).
Shain, A. H. & Pollack, J. R. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE 8, e55119 (2013).
Kadoch, C. et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 45, 592–601 (2013).
Best, S. A. et al. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer. Cell Metab. 34, 874–887.e876 (2022).
Zhao, Y. et al. 5-Fluorouracil enhances the antitumor activity of the glutaminase inhibitor CB-839 against PIK3CA-mutant colorectal cancers. Cancer Res. 80, 4815–4827 (2020).
Lee, C. H. et al. Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double-blinded, placebo-controlled, phase II ENTRATA trial. Clin. Cancer Res. 28, 3248–3255 (2022).
Meric-Bernstam, F. et al. Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial. Clin. Cancer Res. 28, 1540–1548 (2022).
Dong, S. et al. Efficacy of glutamine in treating severe acute pancreatitis: a systematic review and meta-analysis. Front. Nutr. 9, 865102 (2022).
Yong, L., Lu, Q. P., Liu, S. H. & Fan, H. Efficacy of glutamine-enriched nutrition support for patients with severe acute pancreatitis: a meta-analysis. J. Parenter. Enter. Nutr. 40, 83–94 (2016).
Jiang, X. et al. Glutamine supported early enteral therapy for severe acute pancreatitis: a systematic review and meta-analysis. Asia Pac. J. Clin. Nutr. 29, 253–261 (2020).
Asrani, V. et al. Glutamine supplementation in acute pancreatitis: a meta-analysis of randomized controlled trials. Pancreatology 13, 468–474 (2013).
Rastgoo, S. et al. Glutamine supplementation enhances the effects of a low FODMAP diet in irritable bowel syndrome management. Front. Nutr. 8, 746703 (2021).
Arribas-López, E. et al. The effect of amino acids on wound healing: a systematic review and meta-analysis on arginine and glutamine. Nutrients 13, 2498 (2021).
Heyland, D. K. et al. A randomized trial of enteral glutamine for treatment of burn injuries. N. Engl. J. Med. 387, 1001–1010 (2022).
Dollet, L. et al. Glutamine regulates skeletal muscle immunometabolism in type 2 diabetes. Diabetes 71, 624–636 (2022).
Songbo, M. et al. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol. Lett. 307, 41–48 (2019).
Todorova, V. K., Kaufmann, Y., Hennings, L. & Klimberg, V. S. Oral glutamine protects against acute doxorubicin-induced cardiotoxicity of tumor-bearing rats. J. Nutr. 140, 44–48 (2010).
Zhang, J. et al. Beneficial effects of Oridonin on myocardial ischemia/reperfusion injury: insight gained by metabolomic approaches. Eur. J. Pharmacol. 861, 172587 (2019).
Einstein, F. H. et al. Enhanced activation of a “nutrient-sensing” pathway with age contributes to insulin resistance. FASEB J. 22, 3450–3457 (2008).
Petrus, P. et al. Glutamine links obesity to inflammation in human white adipose tissue. Cell Metab. 31, 375–390.e311 (2020).
Li, Q., Taegtmeyer, H. & Wang, Z. V. Diverging consequences of hexosamine biosynthesis in cardiovascular disease. J. Mol. Cell Cardiol. 153, 104–105 (2021).
Doglioni, C. et al. Covid-19 interstitial pneumonia: histological and immunohistochemical features on cryobiopsies. Respiration 100, 488–498 (2021).
Páez-Franco, J. C. et al. Metabolomics analysis reveals a modified amino acid metabolism that correlates with altered oxygen homeostasis in COVID-19 patients. Sci. Rep. 11, 1–12 (2021).
Obayan, A. Overview of the rationale for L-glutamine treatment in moderate-severe COVID-19 infection. J. Infect. Dis. Epidemiol. 7, 23937 (2021). 10.
Cengiz, M. et al. Effect of oral l-Glutamine supplementation on Covid-19 treatment. Clin. Nutr. Exp. 33, 24–31 (2020).
Mohajeri, M., Horriatkhah, E. & Mohajery, R. The effect of glutamine supplementation on serum levels of some inflammatory factors, oxidative stress, and appetite in COVID-19 patients: a case–control study. Inflammopharmacology 29, 1769–1776 (2021).
Luiking, Y. C., Ten Have, G. A., Wolfe, R. R. & Deutz, N. E. Arginine de novo and nitric oxide production in disease states. Am. J. Physiol. Endocrinol. Metab. 303, E1177–1189 (2012).
Morris, S. M. Jr. Enzymes of arginine metabolism. J. Nutr. 134, 2743S–2747S, discussion 2765S-2767S (2004).
Frezza, C. & Mauro, C. Editorial: The metabolic challenges of immune cells in health and disease. Front. Immunol. 6, 293 (2015).
Stechmiller, J. K., Childress, B. & Cowan, L. Arginine supplementation and wound healing. Nutr. Clin. Pract. 20, 52–61 (2005).
Witte, M. B. & Barbul, A. Arginine physiology and its implication for wound healing. Wound Repair Regen. 11, 419–423 (2003).
Blanc, R. S. & Richard, S. Arginine methylation: the coming of age. Mol. Cell. 65, 8–24 (2017).
McBride, A. E. & Silver, P. A. State of the arg: protein methylation at arginine comes of age. Cell 106, 5–8 (2001).
Bedford, M. T. & Clarke, S. G. Protein arginine methylation in mammals: who, what, and why. Mol. Cell 33, 1–13 (2009).
Husson, A. et al. Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. Eur. J. Biochem. 270, 1887–1899 (2003).
Hajji, N. et al. Arginine deprivation alters microglial polarity and synergizes with radiation to eradicate non-arginine-auxotrophic glioblastoma tumors. J. Clin. Investig. 132, e142137 (2022).
Fiedler, T. et al. Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo. Cancer Biol. Ther. 16, 1047–1055 (2015).
Thongkum, A. et al. The combination of arginine deprivation and 5-fluorouracil improves therapeutic efficacy in argininosuccinate synthetase negative hepatocellular carcinoma. Int. J. Mol. Sci. 18, 1175 (2017).
Missiaen, R. et al. GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. Cell Metab. 34, 1151–1167.e1157 (2022).
Kim, R. H. et al. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res. 69, 700–708 (2009).
Bowles, T. L. et al. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int. J. Cancer 123, 1950–1955 (2008).
Di Costanzo, L. et al. Expression, purification, assay, and crystal structure of perdeuterated human arginase I. Arch. Biochem. Biophys. 465, 82–89 (2007).
Morris, S. M. Jr. Regulation of enzymes of the urea cycle and arginine metabolism. Annu. Rev. Nutr. 22, 87–105 (2002).
Hackett, C. S. et al. Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma. Cell Rep. 9, 1034–1046 (2014).
Mao, F.-y et al. CD45+ CD33lowCD11bdim myeloid-derived suppressor cells suppress CD8 + T cell activity via the IL-6/IL-8-arginase I axis in human gastric cancer. Cell Death Dis. 9, 763 (2018).
Su, X. et al. Breast cancer-derived GM-CSF regulates arginase 1 in myeloid cells to promote an immunosuppressive microenvironment. J. Clin. Invest. 131, 131 (2021).
Sousa, M. S., Latini, F. R., Monteiro, H. P. & Cerutti, J. M. Arginase 2 and nitric oxide synthase: Pathways associated with the pathogenesis of thyroid tumors. Free Radic. Biol. Med. 49, 997–1007 (2010).
Vasquez-Dunddel, D. et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J. Clin. Invest. 123, 1580–1589 (2013).
Yu, Y. et al. Arginase‐II promotes melanoma migration and adhesion through enhancing hydrogen peroxide production and STAT3 signaling. J. Cell. Physiol. 235, 9997–10011 (2020).
Steggerda, S. M. et al. Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment. J. Immunother. Cancer 5, 1–18 (2017).
Chiou, Y. S. et al. Piceatannol prevents colon cancer progression via dual-targeting to M2-polarized tumor-associated macrophages and the TGF-beta1 positive feedback signaling pathway. Mol. Nutr. Food Res. 66, e2200248 (2022).
Chiang, K. et al. PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression. Cell Rep. 21, 3498–3513 (2017).
Jin, Y. et al. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia. J. Clin. Invest. 126, 3961–3980 (2016).
Bao, X. et al. CSNK1a1 regulates PRMT1 to maintain the progenitor state in self-renewing somatic tissue. Dev. Cell 43, 227–239.e225 (2017).
Lee, S. H. et al. A feedback loop comprising PRMT7 and miR-24-2 interplays with Oct4, Nanog, Klf4 and c-Myc to regulate stemness. Nucleic Acids Res. 44, 10603–10618 (2016).
Chen, T. Y., Lee, S. H., Dhar, S. S. & Lee, M. G. Protein arginine methyltransferase 7-mediated microRNA-221 repression maintains Oct4, Nanog, and Sox2 levels in mouse embryonic stem cells. J. Biol. Chem. 293, 3925–3936 (2018).
Jeong, H. C. et al. PRMT8 controls the pluripotency and mesodermal fate of human embryonic stem cells by enhancing the PI3K/AKT/SOX2 axis. Stem Cells 35, 2037–2049 (2017).
Liu, L. et al. Arginine and lysine methylation of MRPS23 promotes breast cancer metastasis through regulating OXPHOS. Oncogene 40, 3548–3563 (2021).
Wu, Q. et al. PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. Nat. Chem. Biol. 18, 821–830 (2022).
Dong, F. et al. PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma. Nat. Commun. 9, 4552 (2018).
Han, X. et al. Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro. J. Neurooncol. 118, 61–72 (2014).
Banasavadi-Siddegowda, Y. K. et al. PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells. Oncogene 36, 263–274 (2017).
Huang, T. et al. PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. Mol. Cell. 81, 1276–1291.e1279 (2021).
Liu, C. et al. Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML. Cell Metab. 34, 818–835.e817 (2022).
Durante, W., Johnson, F. K. & Johnson, R. A. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin. Exp. Pharmacol. Physiol. 34, 906–911 (2007).
Harada, D. et al. Oral administration of l-ornithine increases the content of both collagen constituting amino acids and polyamines in mouse skin. Biochem. Biophys. Res. Commun. 512, 712–715 (2019).
Liu, S. et al. Osteocalcin induces proliferation via positive activation of the PI3K/Akt, P38 MAPK pathways and promotes differentiation through activation of the GPRC6A-ERK1/2 pathway in C2C12 myoblast cells. Cell. Physiol. Biochem. 43, 1100–1112 (2017).
Davids, M. & Teerlink, T. Plasma concentrations of arginine and asymmetric dimethylarginine do not reflect their intracellular concentrations in peripheral blood mononuclear cells. Metabolism 62, 1455–1461 (2013).
Bronte, V. et al. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. 24, 302–306 (2003).
Randell, J. C. et al. Effects of substitutions of arginine residues on the basic surface of herpes simplex virus UL42 support a role for DNA binding in processive DNA synthesis. J. Virol. 79, 12025–12034 (2005).
Coburn, L. A. et al. L-arginine supplementation improves responses to injury and inflammation in dextran sulfate sodium colitis. PLoS ONE 7, e33546 (2012).
Shi, H. P. et al. Supplemental L-arginine enhances wound healing following trauma/hemorrhagic shock. Wound Repair Regen. 15, 66–70 (2007).
Witte, M. B., Thornton, F. J., Tantry, U. & Barbul, A. L-Arginine supplementation enhances diabetic wound healing: involvement of the nitric oxide synthase and arginase pathways. Metabolism 51, 1269–1273 (2002).
Chapman, B. R., Mills, K. J., Pearce, L. M. & Crowe, T. C. Use of an arginine‐enriched oral nutrition supplement in the healing of pressure ulcers in patients with spinal cord injuries: an observational study. Nutr. Diet. 68, 208–213 (2011).
Zhu, R. et al. Arginine reduces glycation in gamma(2) subunit of AMPK and pathologies in Alzheimer’s disease model mice. Cells 11, 3520 (2022).
Degrush, E. et al. Cumulative effect of simvastatin, L-arginine, and tetrahydrobiopterin on cerebral blood flow and cognitive function in Alzheimer’s disease. Alzheimers Res. Ther. 14, 134 (2022).
Clemons, G. A. et al. Protein arginine methyltransferase 4 modulates nitric oxide synthase uncoupling and cerebral blood flow in Alzheimer’s disease. J. Cell Physiol. https://doi.org/10.1002/jcp.30858. (2022) Epub ahead of print.
Cottrill, K. A. et al. Exacerbation-prone pediatric asthma is associated with arginine, lysine, and methionine pathway alterations. J. Allergy Clin. Immunol. 151, 118–127.e110 (2023).
Althoff, M. D. et al. Differences in L-arginine metabolism and asthma morbidity among asthma patients with and without obstructive sleep apnea. Respir. Res. 23, 1–8 (2022).
Liao, S. Y. et al. l-Arginine supplementation in severe asthma. JCI Insight 5, e137777 (2020).
Zimmermann, N. et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J. Clin. Invest. 111, 1863–1874 (2003).
Holguin, F. et al. L-Citrulline increases nitric oxide and improves control in obese asthmatics. JCI Insight 4, e131733 (2019).
Gunes Gunsel, G. et al. The arginine methyltransferase PRMT7 promotes extravasation of monocytes resulting in tissue injury in COPD. Nat. Commun. 13, 1303 (2022).
Ahn, B.-Y. et al. PRMT7 ablation in cardiomyocytes causes cardiac hypertrophy and fibrosis through β-catenin dysregulation. Cell. Mol. Life Sci. 79, 99 (2022).
Pyun, J. H. et al. Inducible Prmt1 ablation in adult vascular smooth muscle leads to contractile dysfunction and aortic dissection. Exp. Mol. Med. 53, 1569–1579 (2021).
Zhang, Y. et al. PRMT4 inhibitor TP-064 impacts both inflammatory and metabolic processes without changing the susceptibility for early atherosclerotic lesions in male apolipoprotein E knockout mice. Atherosclerosis 338, 23–29 (2021).
Sun, Q. et al. PRMT1 upregulated by epithelial proinflammatory cytokines participates in COX2 expression in fibroblasts and chronic antigen-induced pulmonary inflammation. J. Immunol. 195, 298–306 (2015).
Eram, M. S. et al. A potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases. ACS Chem. Biol. 11, 772–781 (2016).
Ferla, M. P. & Patrick, W. M. Bacterial methionine biosynthesis. Microbiology 160, 1571–1584 (2014).
Aitken, S. M., Lodha, P. H. & Morneau, D. J. The enzymes of the transsulfuration pathways: active-site characterizations. Biochim. Biophys. Acta 1814, 1511–1517 (2011).
Auger, S., Yuen, W., Danchin, A. & Martin-Verstraete, I. The metIC operon involved in methionine biosynthesis in Bacillus subtilis is controlled by transcription antitermination. Microbiology 148, 507–518 (2002).
Seiflein, T. A. & Lawrence, J. G. Two transsulfurylation pathways in Klebsiella pneumoniae. J. Bacteriol. 188, 5762–5774 (2006).
Pinnen, F. et al. Codrugs linking L-dopa and sulfur-containing antioxidants: new pharmacological tools against Parkinson’s disease. J. Med. Chem. 52, 559–563 (2009).
Fernandes, H. et al. Amino acid deprivation using enzymes as a targeted therapy for cancer and viral infections. Expert Opin. Ther. Pat. 27, 283–297 (2017).
Sanderson, S. M., Gao, X., Dai, Z. & Locasale, J. W. Methionine metabolism in health and cancer: a nexus of diet and precision medicine. Nat. Rev. Cancer 19, 625–637 (2019).
Wang, Z. et al. Methionine is a metabolic dependency of tumor-initiating cells. Nat. Med. 25, 825–837 (2019).
Mavrakis, K. J. et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science 351, 1208–1213 (2016).
Marjon, K. et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis. Cell Rep. 15, 574–587 (2016).
Li, J. T. et al. Dietary folate drives methionine metabolism to promote cancer development by stabilizing MAT IIA. Signal Transduct. Target Ther. 7, 192 (2022).
Kalev, P. et al. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. Cancer Cell 39, 209–224.e211 (2021).
Sachamitr, P. et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma. Nat. Commun. 12, 979 (2021).
Sugimura, T., Birnbaum, S. M., Winitz, M. & Greenstein, J. P. Quantitative nutritional studies with water-soluble, chemically defined diets. VII. Nitrogen balance in normal and tumor-bearing rats following forced feeding. Arch. Biochem. Biophys. 81, 439–447 (1959).
Li, T. et al. Methionine deficiency facilitates antitumour immunity by altering m(6)A methylation of immune checkpoint transcripts. Gut 72, 501–511 (2023).
Cunningham, A. et al. Dietary methionine starvation impairs acute myeloid leukemia progression. Blood 140, 2037–2052 (2022).
Bian, Y. et al. Cancer SLC43A2 alters T cell methionine metabolism and histone methylation. Nature 585, 277–282 (2020).
Xu, Q. et al. HNF4alpha regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer. Nat. Commun. 11, 3978 (2020).
Alshawsh, M. A. et al. A comparison of the gene expression profiles of non-alcoholic fatty liver disease between animal models of a high-fat diet and methionine-choline-deficient diet. Molecules 27, 858 (2022).
Kumar, A. et al. High levels of dietary methionine improves sitagliptin-induced hepatotoxicity by attenuating oxidative stress in hypercholesterolemic rats. Nutr. Metab. 17, 2 (2020).
Lu, S. C. & Mato, J. M. S-adenosylmethionine in liver health, injury, and cancer. Physiol. Rev. 92, 1515–1542 (2012).
Watson, W. H., Burke, T. J., Doll, M. A. & McClain, C. J. S‐Adenosylhomocysteine inhibits NF‐κ B‐mediated gene expression in hepatocytes and confers sensitivity to TNF cytotoxicity. Alcohol. Clin. Exp. Res. 38, 889–896 (2014).
Ganesan, M. et al. Creatine supplementation does not prevent the development of alcoholic steatosis. Alcohol. Clin. Exp. Res. 40, 2312–2319 (2016).
Halsted, C. H. B-Vitamin dependent methionine metabolism and alcoholic liver disease. Clin. Chem. Lab. Med. 51, 457–465 (2013).
Anstee, Q. M. & Day, C. P. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J. Hepatol. 57, 1097–1109 (2012).
King, A. L. et al. The methyl donor S-adenosylmethionine prevents liver hypoxia and dysregulation of mitochondrial bioenergetic function in a rat model of alcohol-induced fatty liver disease. Redox Biol. 9, 188–197 (2016).
Yang, W. et al. Betaine attenuates chronic alcohol‑induced fatty liver by broadly regulating hepatic lipid metabolism. Mol. Med. Rep. 16, 5225–5234 (2017).
Murray, B. et al. Methionine adenosyltransferase α1 is targeted to the mitochondrial matrix and interacts with cytochrome P450 2E1 to lower its expression. Hepatology 70, 2018–2034 (2019).
Barbier-Torres, L. et al. Depletion of mitochondrial methionine adenosyltransferase α1 triggers mitochondrial dysfunction in alcohol-associated liver disease. Nat. Commun. 13, 557 (2022).
Ramalingam, H. et al. A methionine-Mettl3-N6-methyladenosine axis promotes polycystic kidney disease. Cell Metab. 33, 1234–1247.e1237 (2021).
Cooke, D., Ouattara, A. & Ables, G. P. Dietary methionine restriction modulates renal response and attenuates kidney injury in mice. FASEB J. 32, 693–702 (2018).
Lamichhane, S. et al. Circulating metabolites in progression to islet autoimmunity and type 1 diabetes. Diabetologia 62, 2287–2297 (2019).
Feng, X. et al. Hydrogen sulfide from adipose tissue is a novel insulin resistance regulator. Biochem. Biophys. Res. Commun. 380, 153–159 (2009).
Wanders, D. et al. Transcriptional impact of dietary methionine restriction on systemic inflammation: relevance to biomarkers of metabolic disease during aging. BioFactors 40, 13–26 (2014).
Weichselbaum, R. R., Liang, H., Deng, L. & Fu, Y.-X. Radiotherapy and immunotherapy: a beneficial liaison? Nat. Rev. Clin. Oncol. 14, 365–379 (2017).
Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv324–328rv324 (2016).
Ma, N. et al. Nutrients mediate intestinal bacteria–mucosal immune crosstalk. Front. Immunol. 9, 5 (2018).
Zheng, Y. et al. Anergic T cells are metabolically anergic. J. Immunol. 183, 6095–6101 (2009).
Hidayat, S. et al. Inhibition of amino acid-mTOR signaling by a leucine derivative induces G1 arrest in Jurkat cells. Biochem. Biophys. Res. Commun. 301, 417–423 (2003).
Yao, C.-c et al. Accumulation of branched-chain amino acids reprograms glucose metabolism in CD8 + T cells with enhanced effector function and anti-tumor response. Cell Rep. 42, 112186 (2023).
Wang, Z. et al. Leucine-tRNA-synthase-2-expressing B cells contribute to colorectal cancer immunoevasion. Immunity 55, 1067–1081.e1068 (2022).
Ikeda, K. et al. Slc3a2 mediates branched-chain amino-acid-dependent maintenance of regulatory T cells. Cell Rep. 21, 1824–1838 (2017).
Liu, Y. et al. SLC7A5 is a lung adenocarcinoma-specific prognostic biomarker and participates in forming immunosuppressive tumor microenvironment. Heliyon 8, e10866 (2022).
Zhu, Q. et al. Bioinformatics prediction and in vivo verification identify SLC7A5 as immune infiltration related biomarker in breast cancer. Cancer Manag. Res. 14, 2545–2559 (2022).
Eckerle, S. et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 23, 2129–2138 (2009).
Yi, L. et al. Enrichment of branched chain amino acid transaminase 1 correlates with multiple biological processes and contributes to poor survival of IDH1 wild-type gliomas. Aging 13, 3645 (2021).
Silva, L. S. et al. Branched-chain ketoacids secreted by glioblastoma cells via MCT1 modulate macrophage phenotype. EMBO Rep. 18, 2172–2185 (2017).
Mo, B.-Y. et al. The underlying molecular mechanism and identification of transcription factor markers for laryngeal squamous cell carcinoma. Bioengineered 12, 208–224 (2021).
Wang, H. et al. Aspartate metabolism facilitates IL-1β production in inflammatory macrophages. Front. Immunol. 12, 753092 (2021).
Jha, A. K. et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 42, 419–430 (2015).
Bailis, W. et al. Distinct modes of mitochondrial metabolism uncouple T cell differentiation and function. Nature 571, 403–407 (2019).
Newsholme, P. Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J. Nutr. 131, 2515S–2522S (2001).
Curi, R. et al. Glutamine‐dependent changes in gene expression and protein activity. Cell Biochem. Funct. 23, 77–84 (2005).
Roth, E. et al. Regulative potential of glutamine—relation to glutathione metabolism. Nutrition 18, 217–221 (2002).
Hiscock, N. et al. Glutamine supplementation further enhances exercise-induced plasma IL-6. J. Appl. Physiol. 95, 145–148 (2003).
Edwards, D. N. et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J. Clin. Investig. 131, e140100 (2021).
Fu, Q. et al. Tumor-associated macrophage-derived interleukin-23 interlinks kidney cancer glutamine addiction with immune evasion. Eur. Urol. 75, 752–763 (2019).
Yang, W.-H. et al. Enhancing the efficacy of glutamine metabolism inhibitors in cancer therapy. Trends Cancer 7, 790–804 (2021).
Johnson, M. O. et al. Distinct regulation of Th17 and Th1 cell differentiation by glutaminase-dependent metabolism. Cell 175, 1780–1795.e1719 (2018).
Rais, R. et al. Discovery of 6-diazo-5-oxo-l-norleucine (DON) prodrugs with enhanced CSF delivery in monkeys: a potential treatment for glioblastoma. J. Med. Chem. 59, 8621–8633 (2016).
Leone, R. D. et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science 366, 1013–1021 (2019).
Oh, M.-H. et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J. Clin. Investig. 130, 3865–3884 (2020).
Byun, J.-K. et al. Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity. Mol. Cell 80, 592–606.e598 (2020).
Li, Q. et al. Inhibitor of glutamine metabolism V9302 promotes ROS-induced autophagic degradation of B7H3 to enhance antitumor immunity. J. Biol. Chem. 298, 101753 (2022).
Osunkoya, B., Adler, W. & Smith, R. Effect of arginine deficiency on synthesis of DNA and immunoglobulin receptor of Burkitt lymphoma cells. Nature 227, 398–399 (1970).
Daly, J. M. et al. Immune and metabolic effects of arginine in the surgical patient. Ann. Surg. 208, 512 (1988).
Bower, R. H. et al. Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit. Care Med. 23, 436–449 (1995).
Powell-Tuck, J. Nutritional interventions in critical illness. Proc. Nutr. Soc. 66, 16–24 (2007).
De Waele, E., Malbrain, M. L. & Spapen, H. Nutrition in sepsis: a bench-to-bedside review. Nutrients 12, 395 (2020).
Weissman, A. M. et al. Tyrosine phosphorylation of the human T cell antigen receptor zeta-chain: activation via CD3 but not CD2. J. Immunol. 141, 3532–3536 (1988).
Rodriguez, P. C. et al. Regulation of T cell receptor CD3zeta chain expression by L-arginine. J. Biol. Chem. 277, 21123–21129 (2002).
Minami, Y., Weissman, A. M., Samelson, L. E. & Klausner, R. D. Building a multichain receptor: synthesis, degradation, and assembly of the T-cell antigen receptor. Proc. Natl Acad. Sci. USA 84, 2688–2692 (1987).
Bansal, V. et al. Citrulline can preserve proliferation and prevent the loss of CD3 ζ chain under conditions of low arginine. J. Parenter. Enter. Nutr. 28, 423–430 (2004).
Fletcher, M. et al. l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cellssuppression of T-cell responses by L-arginine depletion. Cancer Res. 75, 275–283 (2015).
Li, P. et al. Amino acids and immune function. Br. J. Nutr. 98, 237–252 (2007).
Martí, I. et al. Mitochondrial arginase-2 is a cell‑autonomous regulator of CD8 + T cell function and antitumor efficacy. JCI insight 4, e132975 (2019).
Lowe, M. M. et al. Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues. JCI insight 4, e129756 (2019).
Aaboe Jørgensen, M. et al. Arginase 1–based immune modulatory vaccines induce anticancer immunity and synergize with Anti–PD-1 checkpoint blockadeARG1 vaccines induce antitumor immunity in combo with anti–PD-1. Cancer Tmmunol. Res. 9, 1316–1326 (2021).
Fedoriw, A. et al. Inhibiting type I arginine methyltransferase activity promotes T cell–mediated antitumor immune responses. Cancer Immunol. Res. 10, 420–436 (2022).
Zheng, N.-N. et al. Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression. World J. Gastroenterol. 26, 3737 (2020).
Fu, L. et al. A mitochondrial STAT3-methionine metabolism axis promotes ILC2-driven allergic lung inflammation. J. Allergy Clin. Immunol. 149, 2091–2104 (2022).
Guo, R. et al. Methionine metabolism controls the b cell ebv epigenome and viral latency. Cell Metab. 34, 1280–1297.e1289 (2022).
Saini, N. et al. Methionine uptake via the SLC43A2 transporter is essential for regulatory T-cell survival. Life Sci. Alliance 5, e202201663 (2022).
Hung, M. H. et al. Tumor methionine metabolism drives T-cell exhaustion in hepatocellular carcinoma. Nat. Commun. 12, 1455 (2021).
Zhang, Y. et al. Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer. J. Immunother. Cancer 9, e001364 (2021).
Daou, N. et al. A novel, multitargeted endogenous metabolic modulator composition impacts metabolism, inflammation, and fibrosis in nonalcoholic steatohepatitis-relevant primary human cell models. Sci. Rep. 11, 11861 (2021).
Chakravarthy, M. et al. Mechanistic insights into the multimodal effects of AXA1125 in T2D subjects with NAFLD. Hepatology 70, 1264A–1264A (2019).
Harrison, S. A. et al. Safety, tolerability, and biologic activity of AXA1125 and AXA1957 in subjects with nonalcoholic fatty liver disease. Am. J. Gastroenterol. 116, 2399 (2021).
Lu, Z. et al. BCATc inhibitor 2 ameliorated mitochondrial dysfunction and apoptosis in oleic acid-induced non-alcoholic fatty liver disease model. Front. Pharmacol. 13, 1025551 (2022).
Vanweert, F. et al. A randomized placebo-controlled clinical trial for pharmacological activation of BCAA catabolism in patients with type 2 diabetes. Nat. Commun. 13, 3508 (2022).
Okano, N. et al. First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Invest. N. Drugs 38, 1495–1506 (2020).
Romeike, B. F. et al. Action and efficacy of p-[131I] iodo-L-phenylalanine on primary human glioma cell cultures and rats with C6-gliomas. Anticancer Res. 24, 3971–3976 (2004).
Filss, C. P. et al. Flare phenomenon in O-(2-18F-fluoroethyl)-l-tyrosine PET after resection of gliomas. J. Nucl. Med. 61, 1294–1299 (2020).
Rosenzweig, A., Blenis, J. & Gomes, A. P. Beyond the Warburg effect: how do cancer cells regulate one-carbon metabolism? Front. Cell Dev. Biol. 6, 90 (2018).
Hayashi, R. J. et al. Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from Children’s Oncology Group AALL0434. J. Clin. Oncol. 38, 3062 (2020).
Lin, T. et al. A randomized phase I study to evaluate the safety, tolerability, and pharmacokinetics of recombinant Erwinia asparaginase (JZP‐458) in healthy adult volunteers. J. Clin. Transl. Sci. 14, 870–879 (2021).
Maese, L. et al. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood 141, 704–712 (2023).
Yau, T. et al. A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients. Invest. N. Drugs 40, 314–321 (2022).
Lorentzen, C. L. et al. Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors–A phase I trial. Front. Immunol. 13, 1023023 (2022).
Chang, K.-Y. et al. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. Oncoimmunology 10, 1943253 (2021).
Hall, P. E. et al. A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade GliomaArginine Deprivation Therapy in Recurrent High-grade Gliomas. Clin. Cancer Res. 25, 2708–2716 (2019).
Jensen-Pergakes, K. et al. SAM-competitive PRMT5 inhibitor PF-06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance discovery of SAM-competitive PRMT5 inhibitor PF-06939999. Mol. Cancer Ther. 21, 3–15 (2022).
Fedoriw, A. et al. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Cancer Cell 36, 100–114.e125 (2019).
Pore, N. et al. Discovery and development of MEDI7247, a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological cancers. Blood 132, 4071 (2018).
Atkinson, S. J., Evans, L. & Scott, J. S. A patent review of MAT2a inhibitors (2018–2021). Expert Opin. Ther. Pat. 32, 1043–1053 (2022).
Konteatis, Z. et al. Discovery of AG-270, a first-in-class oral MAT2A inhibitor for the treatment of tumors with homozygous MTAP deletion. J. Med. Chem. 64, 4430–4449 (2021).
Huckaba, C. E. & Keyes, F. G. The accuracy of estimation of hydrogen peroxide by potassium permanganate titration. J. Am. Chem. Soc. 70, 1640–1644 (1948).
Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27–30 (1995).
Towbin, H. et al. Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors. J. Biol. Chem. 278, 52964–52971 (2003).
Dumez, H. et al. A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer. Anti-Cancer Drugs 18, 219–225 (2007).
Wang, J. et al. Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 63, 7861–7869 (2003).
Morowitz, M. J. et al. Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clin. Cancer Res. 11, 2680–2685 (2005).
Sheppard, G. S. et al. Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding. J. Med. Chem. 49, 3832–3849 (2006).
Kawai, M. et al. Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg. Med. Chem. Lett. 16, 3574–3577 (2006).
Tucker, L. et al. Ectopic expression of methionine aminopeptidase-2 causes cell transformation and stimulates proliferation. Oncogene 27, 3967–3976 (2008).
Tabe, Y., Lorenzi, P. L. & Konopleva, M. Amino acid metabolism in hematologic malignancies and the era of targeted therapy. Blood 134, 1014–1023 (2019).
Hillier, J. et al. The BCAT1 CXXC motif provides protection against ROS in acute myeloid leukaemia cells. Antioxidants 11, 683 (2022).
Hattori, A. et al. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia. Nature 545, 500–504 (2017).
Brunetti-Pierri, N. et al. Phenylbutyrate therapy for maple syrup urine disease. Hum. Mol. Genet. 20, 631–640 (2011).
Zhang, W. et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat. Cell Biol. 14, 276–286 (2012).
Ehsanipour, E. A. et al. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. Cancer Res. 73, 2998–3006 (2013).
Bertero, T. et al. Tumor-stroma mechanics coordinate amino acid availability to sustain tumor growth and malignancy. Cell Metab. 29, 124–140.e110 (2019).
Schellekens, H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24, 1720–1740 (2002).